Biomedical Engineering Reference
In-Depth Information
CHAPTER 12
Nonviral Vector Recombinant
Mesenchymal Stem Cells: A
Promising Targeted-Delivery
Vehicle in Cancer Gene Therapy
d
n
4
y
3
n
g
|
1
YU-LAN HU
a
, YING-HUA FU
b
, YASUHIKO TABATA
c
AND JIAN-QING GAO*
a
a
Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang
University, P. R. China;
b
Department of Pharmaceutics, School of Medicine,
Jiaxing University, P. R. China;
c
Department of Biomaterials, Institute for
Frontier Medical Sciences, Kyoto University, Japan
*
E-mail: gaojianqing1029@yahoo.com.cn
12.1 Introduction
With the development of molecular biology, cancer gene therapy becomes a
promising field in the treatment of malignant tumors. Cytokines, such as IL-2,
IL-12, and IFN-b, can stimulate antitumor responses through the activation of
T cells, which mediates immune response to eliminate tumors. Nevertheless,
the therapeutic application of exogenously administered cytokines is limited by
their short half-lives and poor accessibility to tumor sites.
1
These cytokines
exhibit rapid blood clearance and poor retention times in the target, which
results in the necessity for frequent administration of such agents. Therefore,
therapeutic utility of these cytokines in vivo is limited by its excessive toxicity
when
frequency.
1
administered
systemically
at high
doses and with
high
